Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation

The treatment strategy in multiple myeloma (MM) is to get complete remission followed by high-dose chemotherapy and autologous Hematopoietic Stem Cell Transplantation (HSCT). Neoplastic Plasma Cells (NPCs) are CD45(-/dim), CD38(+high), CD138(+), CD19(-), and  CD56(+high) in most cases. The description of this immunophenotype is of major importance as it leads to the correct identification of mi...

Minimal residual disease detection of leukemic cells in ovarian cortex by eight-color flow cytometry.

STUDY QUESTION How can leukemic cells be detected in cryopreserved ovarian tissue? SUMMARY ANSWER Multicolor flow cytometry (FCM) is useful to evaluate the presence of viable leukemic cells in the ovarian cortex with a high specificity and a robust sensitivity. WHAT IS KNOWN ALREADY Storing ovarian tissue is an option to preserve fertility before gonadotoxic radiotherapy or chemotherapy tre...

Minimal residual disease detection in cryopreserved ovarian tissue by multicolor flow cytometry in acute myeloid leukemia.

The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.

The presence of minimal residual disease (MRD) in the bone marrow (BM) of patients with acute myeloid leukemia (AML) following chemotherapy has been established by many studies to be strongly associated with relapse of leukemia. In addition, detection of MRD is the major objective of many of the newer diagnostic techniques used in malignant hematology. Because of the wide availability and conce...

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

In this retrospective study, we evaluated the impact of pre- and posttransplant minimal residual disease (MRD) detected by multiparametric flow cytometry (MFC) on outcome in 160 patients with ALL who underwent myeloablative allogeneic hematopoietic cell transplantation (HCT). MRD was defined as detection of abnormal B or T cells by MFC with no evidence of leukemia by morphology (<5% blasts in m...